Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brogidirsen - Nippon Shinyaku

Next Previous
Search
Drug Profile

Brogidirsen - Nippon Shinyaku

Alternative Names: Exon 44 skipping antisense oligonucleotide; Exon 44 skipping DMD therapeutic; NS-089/NCNP-02

Latest Information Update: 19 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nippon Shinyaku
  • Class Antisense oligonucleotides
  • Mechanism of Action Dystrophin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy

Most Recent Events

  • 05 Jan 2024 Phase-II clinical trials in Duchenne muscular dystrophy (In children, In adolescents) in USA (IV) (NCT05996003)
  • 13 Dec 2023 Brogidirsen - Nippon Shinyaku receives Orphan Drug status for Duchenne muscular dystrophy in European Union
  • 09 Aug 2023 Brogidirsen receives Breakthrough Therapy status for Duchenne muscular dystrophy in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top